Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980823 | 0.87 | TDP1 (0.34) | CYP11B1CYP11B2HSP90AA1 | |
| SCHEMBL690067 | 0.84 | MEN1 (0.36) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL23532128 | 0.83 | CYP11B1 (0.36) | CYP11B1CYP11B2KCNN4KCNA3MEN1 | |
| SCHEMBL21293423 | 0.83 | CYP11B1 (0.36) | CYP11B1CYP11B2KCNN4KCNA3MEN1 | |
| SCHEMBL8390628 | 0.83 | CYP11B1 (0.36) | CYP11B1CYP11B2KCNN4KCNA3MEN1 | |
| SCHEMBL7969401 | 0.82 | AKR1B1 (0.36) | CYP11B1CYP11B2KMT2ATSHR | |
| SCHEMBL28988475 | 0.80 | TAAR1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL27469137 | 0.80 | TDP1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL21293520 | 0.80 | PGK1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL688676 | 0.80 | KEAP1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240376113-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| US-12091412-B2 | Heterocyclic inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-112638376-B | Substituted tetrahydrocyclopenta [ c ] pyrroles, substituted dihydropyrrolidines, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| CN-110678463-B | Substituted nitrogen-containing compounds | 百时美施贵宝公司 | 2023-06-06 | — | — | CN | disclosed |
| US-6468995-B1 | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-0667868-B1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-0783495-B1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LTD (GB) | 2002-02-27 | — | — | EP | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0783495-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | Pfizer Limited (GB) | 1997-07-16 | — | — | EP | disclosed |
| EP-0730408-A1 | TRIAZOLE PHOSPHONATE PESTICIDES | AgrEvo UK Limited (GB) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| CN-1116425-A | New cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-02-07 | — | — | CN | disclosed |
| WO-1995014385-A1 | TRIAZOLE PHOSPHONATE PESTICIDES | AGREVO UK LIMITED (GB) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995007283-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | CYP11B1 51/4885CYP11B2 168/4885SORD 1619/4885 |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | CYP11B1 1326/4885CYP11B2 1455/4885SORD 2815/4885 |
| US-20240376113-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | CYP11B1 1326/4885CYP11B2 1455/4885SORD 2815/4885 |
| US-12091412-B2 | Heterocyclic inhibitors of ENPP1 | ENPP1, ENPP3, ENPP2 | CYP11B1 1326/4885CYP11B2 1455/4885SORD 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.